WSJ
17 Aug 2026, 06:48 UTC · 1h ago
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
WSJ
17 Aug 2026, 06:48 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
The clinical trial for volrustomig plus chemotherapy has been stopped because it is unlikely to reach its primary endpoints. — Failure to meet primary endpoints in a clinical trial typically leads to significant devaluation of the drug candidate and the associated company's stock.
-0.90Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Stocks most exposed
Modeled from each name's sensitivity to this story
PRNewsWire
4h ago
